Oncolytics Biotech Inc
ONCYFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Oncolytics Biotech Inc Makes Money
No flow chart is shown because the available revenue and expense lines do not reconcile exactly. The reported financial history below remains available.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 11 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 3, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| MAI Capital Management | 2026-03-31 | 526 | $447 | SEC filing |
| COMMONWEALTH EQUITY SERVICES, LLC | 2026-03-31 | 35,114 | $29.8K | SEC filing |
| CIBC WORLD MARKET INC. | 2026-03-31 | 60,303 | $51.3K | SEC filing |
| Crestwood Advisors Group, LLC | 2026-03-31 | 10,000 | $8.49K | SEC filing |
| JPMORGAN CHASE & CO | 2026-03-31 | 1,277 | $1.03K | SEC filing |
| EVOLUTION WEALTH MANAGEMENT INC. | 2026-03-31 | 105 | $89 | SEC filing |
| SECURITY NATIONAL BANK OF SIOUX CITY IOWA /IA/ | 2026-03-31 | 33,255 | $28.2K | SEC filing |
| PNC FINANCIAL SERVICES GROUP, INC. | 2026-03-31 | 15,055 | $12.8K | SEC filing |
| WELLS FARGO & COMPANY/MN | 2026-03-31 | 6,602 | $5.6K | SEC filing |
| GEODE CAPITAL MANAGEMENT, LLC | 2026-03-31 | 66,939 | $56.8K | SEC filing |
| Ball & Co Wealth Management Inc. | 2026-03-31 | 38,253 | Not shown | SEC filing |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2026-03-31 | 41,323 | $35.1K | SEC filing |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 2026-03-31 | 6,393 | $5.43K | SEC filing |
| BANK OF MONTREAL /CAN/ | 2026-03-31 | 44,484 | $37.8K | SEC filing |
| FRANKLIN RESOURCES INC | 2026-03-31 | 69,842 | $71.3K | SEC filing |
| XTX Topco Ltd | 2026-03-31 | 109,758 | $93.2K | SEC filing |
| CWM, LLC | 2026-03-31 | 1,325 | $1.13K | SEC filing |
| Cedar Mountain Advisors, LLC | 2026-03-31 | 5,651 | $4.8K | SEC filing |
| TOCQUEVILLE ASSET MANAGEMENT L.P. | 2026-03-31 | 149,000 | $126K | SEC filing |
| TWO SIGMA SECURITIES, LLC | 2026-03-31 | 25,627 | $21.8K | SEC filing |
- Each value is checked against Oncolytics Biotech Inc's share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 1 row: the filed value is about 1,000 times too small for the share count at Oncolytics Biotech Inc's share price.
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security.
- Creative Planning: 13,330 shares reported 2025-12-31; 14,545 shares reported 2026-03-31.
- Aviso Financial Inc.: 52 shares reported 2025-12-31; 1,304 shares reported 2026-03-31.
- JONES FINANCIAL COMPANIES LLLP: 2,053 shares reported 2025-12-31; 4,278 shares reported 2026-03-31.
- Kingsview Wealth Management, LLC: 11,210 shares reported 2025-12-31; 11,210 shares reported 2026-03-31.
- SeaCrest Wealth Management, LLC: 32,000 shares reported 2025-12-31; 32,000 shares reported 2026-03-31.
- Vantage Point Financial LLC: 29,744 shares reported 2025-12-31; 29,744 shares reported 2026-03-31.
- HEADINVEST, LLC: 44,700 shares reported 2025-12-31; 44,700 shares reported 2026-03-31.
- RAYMOND JAMES FINANCIAL INC: 33,368 shares reported 2025-12-31; 33,751 shares reported 2026-03-31.
- UBS Group AG: 22,896 shares reported 2025-12-31; 50,559 shares reported 2026-03-31.
- TD Waterhouse Canada Inc.: 400 shares reported 2025-12-31; 662 shares reported 2026-03-31.
- Cerity Partners LLC: 10,000 shares reported 2025-12-31; 10,000 shares reported 2026-03-31.
- PROFESSIONAL ADVISORY SERVICES INC: 20,000 shares reported 2025-12-31; 20,000 shares reported 2026-03-31.
Showing the 12 most recent filer reports.
35 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Oncolytics Biotech Inc's recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-02-11 · Seizinger Bernd R.: Larger than 12 of the 13 other insider purchases of Common Shares on file. SEC filing
- 2026-01-16 · Seizinger Bernd R.: Larger than all 13 other insider purchases of Common Shares on file. SEC filing
Independent insiders buying near the same time
- 2026-03-11–2026-03-12: 2 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing )
- 2026-02-11–2026-02-12: 11 event(s) across 9 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing , filing , filing , filing , filing , filing , filing , filing )
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-03-12 | Kelly Jared · Chief Executive Officer | Common Shares | P — Open market or private purchase | +5,050 | 0.96 | SEC filing |
| 2026-03-11 | Parsons James T. · Director | Common Shares | P — Open market or private purchase | +10,000 | 1.03 | SEC filing |
| 2026-02-12 | Hagerman Allison · VP, Product Development | Common Shares | P — Open market or private purchase | +10,000 | 0.83 | SEC filing |
| 2026-02-12 | Andrews Patricia S · Director | Common Shares | P — Open market or private purchase | +35,400 | 0.86 | SEC filing |
| 2026-02-12 | Pisano Wayne · Director | Common Shares | P — Open market or private purchase | +30,000 | 0.84 | SEC filing |
| 2026-02-12 | Heineman Thomas Charles · Chief Medical Officer | Common Shares | P — Open market or private purchase | +12,132 | 0.83 | SEC filing |
| 2026-02-12 | Look Kirk · Chief Financial Officer | Common Shares | P — Open market or private purchase | +12,000 | 0.84 | SEC filing |
| 2026-02-12 | Brown Deborah Margaret · Director | Common Shares | P — Open market or private purchase | +25,000 | 0.85 | SEC filing |
Showing 8 of 10 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-01 | McAdory John Bearden · Chief Operating Officer | Stock Option | A — Grant, award, or other acquisition | +145,000 | SEC filing |
| 2026-06-01 | Glover Stephen C. · Director | Stock Option | A — Grant, award, or other acquisition | +96,000 | SEC filing |
| 2026-06-01 | Heineman Thomas Charles · Chief Medical Officer | Stock Option | A — Grant, award, or other acquisition | +260,000 | SEC filing |
| 2026-06-01 | Seizinger Bernd R. · Director | Stock Option | A — Grant, award, or other acquisition | +30,000 | SEC filing |
| 2026-06-01 | Aromando Andrew · Chief Business Officer | Stock Option | A — Grant, award, or other acquisition | +260,000 | SEC filing |
| 2026-06-01 | Pisano Wayne · Director | Stock Option | A — Grant, award, or other acquisition | +30,000 | SEC filing |
| 2026-06-01 | Parsons James T. · Director | Stock Option | A — Grant, award, or other acquisition | +30,000 | SEC filing |
| 2026-06-01 | Hagerman Allison · Chief Technology Officer | Stock Option | A — Grant, award, or other acquisition | +260,000 | SEC filing |
Showing 8 of 10 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.